Swiss Group for Clinical Cancer Research

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Private

Established: 1965-01-01

Employees: -

Market Cap: -

Website: http://www.sakk.ch/

Clinical Trials

Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Liver Cancer

Interventions: Drug: sunitinib malate

First Posted Date: 2007-08-09

Last Posted Date: 2012-06-26

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 45

Registration Number: NCT00514228

Locations: 🇨🇭
Kantonsspital - St. Gallen, St. Gallen, Switzerland

E-MOSAIC Electronic Tool to Monitor Symptoms

Completed

Conditions: Cancer

First Posted Date: 2007-05-24

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 264

Registration Number: NCT00477919

Locations: 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland
🇨🇭
Spital Buelach, Bulach, Switzerland

and more 4 locations

Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2007-03-09

Last Posted Date: 2012-06-28

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 43

Registration Number: NCT00445406

Locations: 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland

Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery

Phase 1

Completed

Conditions: Esophageal Cancer

First Posted Date: 2007-03-09

Last Posted Date: 2012-06-11

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 27

Registration Number: NCT00445861

Locations: 🇨🇭
Kantonsspital - St. Gallen, St. Gallen, Switzerland
🇨🇭
Klinik Stephanshorn, St. Gallen, Switzerland

Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: ibritumomab tiuxetan
Drug: rituximab
Drug: melphalan
Drug: vinorelbine tartrate / G-CSF
Procedure: autologous hematopoietic stem cell harvesting and transplantation

First Posted Date: 2006-10-26

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 20

Registration Number: NCT00392691

Locations: 🇨🇭
Saint Claraspital AG, Basel, Switzerland
🇨🇭
Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland
🇨🇭
Kantonsspital Liestal, Bern, Switzerland

and more 7 locations

Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2006-07-20

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 104

Registration Number: NCT00354549

Locations: 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇨🇭
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

Phase 2

Completed

Conditions: Malignant Mesothelioma

Interventions: Drug: Cisplatin
Drug: Pemetrexed
Procedure: Therapeutic conventional surgery
Radiation: Radiotherapy

First Posted Date: 2006-06-08

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 153

Registration Number: NCT00334594

Locations: 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇨🇭
Inselspital Bern, Bern, Switzerland
🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland

and more 10 locations

Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases

Phase 2

Completed

Conditions: Lung Cancer
Metastatic Cancer

Interventions: Drug: temozolomide
Drug: gefitinib
Radiation: radiation therapy

First Posted Date: 2005-10-13

Last Posted Date: 2012-06-05

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 59

Registration Number: NCT00238251

Locations: 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇨🇭
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland

Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: Docetaxel and Cisplatin
Radiation: Radiotherapy

First Posted Date: 2005-10-13

Last Posted Date: 2012-06-05

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 21

Registration Number: NCT00238407

Locations: 🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland
🇨🇭
Regionalspital, Thun, Switzerland
🇨🇭
Kantonsspital Bruderholz, Bruderholz, Switzerland

and more 7 locations

Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab + Letrozole

First Posted Date: 2005-10-13

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 13

Registration Number: NCT00238290

Locations: 🇨🇭
Kantonsspital Bruderholz, Bruderholz, Switzerland
🇨🇭
Ospedale Beata Vergine, Mendrisio, Switzerland
🇨🇭
Saint Claraspital AG, Basel, Switzerland

and more 11 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy